Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis After Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Monzr M. Al Malki(Johns Hopkins Hospital), Antonio Jiménez(University of Miami), Mehdi Hamadani(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Farhad Khimani(Moffitt Cancer Center), Brent R. Logan(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Medhat Askar(Baylor University Medical Center), Bronwen E. Shaw(Medical College of Wisconsin), Muna Qayed(Emory University), Martin Maiers(National Marrow Donor Program), Sally Arai(Stanford Medicine), Erin Leckrone(National Marrow Donor Program), Alison W. Loren(University of Pennsylvania), Mahasweta Gooptu(Dana-Farber Cancer Institute), Stephanie Bo‐Subait(National Marrow Donor Program), Karen K. Ballen(Massachusetts General Hospital), Heather E. Stefanski(National Marrow Donor Program), Sung Won Choi(University of Michigan), Sarah Smith(National Marrow Donor Program), Brian C. Shaffer(Memorial Sloan Kettering Cancer Center), Stephen R. Spellman(National Marrow Donor Program), Jianqun Kou(East Tennessee State University), Stephanie Fingerson(National Marrow Donor Program), Rachel J. Cook(Oregon Health & Science University), Abeer Madbouly(National Marrow Donor Program), Jeffery J. Auletta(NHS Blood and Transplant), Dipenkumar Modi(Wayne State University), Larisa Broglie(Medical College of Wisconsin), Karilyn Larkin(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Juan Wu(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Craig Malmberg(National Marrow Donor Program), Steven M. Devine(National Marrow Donor Program), Janelle A. Olson(National Marrow Donor Program), Rachel Cusatis(Medical College of Wisconsin)
Cited by 23
Related Papers
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.1k
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes
|Journal of Clinical Oncology|2017|664
Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma
|New England Journal of Medicine|2018|584
Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease
|Journal of Clinical Oncology|2019|441